Ajanta Pharma Soars 3.5% on Motilal Oswal's Bullish Outlook for New Weight-Loss Drug

• Ajanta Pharma shares rose 3.5% intraday after Motilal Oswal projected strong gains from its new weight-loss drug.
• Motilal Oswal reiterated a 'buy' rating with a target price of Rs 3,145, implying a 17% upside.
• The company partnered with Biocon to source semaglutide, a weight-loss drug, for Asia and Africa markets.
• Brokerage estimates annualised sales of USD 25-30 million from semaglutide by H2 FY28, with 50-55% EBITDA margins.
• Motilal Oswal expects Ajanta Pharma's revenue and profit to grow at 11% and 16% CAGR respectively over FY26-28.

Why It Matters: Motilal Oswal's 'buy' rating and strong projections for Ajanta Pharma's new weight-loss drug fueled stock gains.